Related Experiment Video
Updated: Jan 8, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Neighborhood Deprivation Linked to Medication Level Variability in Liver Transplant Recipients
Laila Fozouni1, Giuseppe Cullaro2, Ann Lazar3
1Department of Medicine, University of California, San Francisco, California, USA.
Background:
Neighborhood deprivation is associated with adverse outcomes post-liver transplantation in pediatric recipients. We examined the association between neighborhood deprivation index (NDI) and medication level variability index (MLVI), T-cell mediated rejection (TCMR), and graft failure/death in adult liver transplant recipients.
Methods:
We conducted a retrospective cohort study of 1485 adult liver-transplant recipients with >1 year follow-up. NDI was calculated at the census tract level. MLVI, the standard deviation of ≥3 sequential tacrolimus troughs, was dichotomized at MLVI > 2. Hospitalization was analyzed as a binary variable.
Results:
The median age was 65, and 36% were female. In multivariate regression, increased NDI was associated with 20% increased odds of MLVI > 2 between 1-3 years post-transplant (95% CI 1.1-1.3) but not MLVI > 2 between 3-5 years. NDI was associated with a 2.2 times higher hazard of hospitalization between 1-3 years post-transplant (95% CI 1.1-4.4); but not between 3-5 years (HR 1.9, 95% CI 1.0-3.7). NDI was not significantly associated with increased hazard of rejection or graft failure/death. Adjusting for NDI, MLVI > 2 between 1-3 and 3-5 years was associated with a 30% higher hazard of rejection (95% CI 1.1-1.6), and between 1-3 years, a 40% increased hazard of graft failure/death (95% CI 1.2-1.5). We found geospatial hotspots of rejection with positive autocorrelation at Years 1-3 and 3-5 post-transplant (Geary's C 0.97, p = 0.01).
Conclusions:
Efforts to understand why individuals from disadvantaged neighborhoods experience poorer immunosuppression adherence may uncover targeted strategies to improve medication adherence for high-risk groups.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Dosage Regimen: Individualization
Therapeutic Drug Monitoring: Affecting Factors

